Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination

1,2:5,6-Dianhydrogalactitol (DAG) is a bifunctional DNA-targeting agent causing N(7)-guanine alkylation and inter-strand DNA crosslinks currently in clinical trial for treatment of glioblastoma. While preclinical studies and clinical trials have demonstrated antitumor activity of DAG in a variety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Beibei, Steinø, Anne, Bacha, Jeffrey, Brown, Dennis, Daugaard, Mads
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170372/
https://www.ncbi.nlm.nih.gov/pubmed/30283085
http://dx.doi.org/10.1038/s41419-018-1069-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170372/
https://www.ncbi.nlm.nih.gov/pubmed/30283085
http://dx.doi.org/10.1038/s41419-018-1069-9

Ejemplares similares